Gloucester Pharmaceuticals, Inc. Announces FDA Advisory Committee Meeting to Discuss Romidepsin New Drug Application
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC) meeting on September 2, 2009.